In traditional Chinese medicine (TCM) theory, pathogenic heat and toxins, which are akin to the inflammatory factors, are the causes of cancer and could promote its virulent development. Therefore, heat-clearing and detoxicating (HCD) herbs are essential components of TCM formulas for cancer treatment. An increasing interest has been focused on the study of HCD herbs and accumulated evidences have shown that HCD herbs or HCD herbs-based formulas exhibited remarkable anticancer effects when used alone or combined with other therapeutic approaches. Some of the HCD herb-derived products have been tested in clinical trials. Studies revealed that extracts or pure compounds of the HCD herbs showed a broad anticancer spectrum against both solid and hematologic malignancies without significant toxic effects. Notably, some HCD herbs or formulas could strongly enhance the anticancer activities of chemo- or radio-therapy and alleviate their side effects. The anticancer activities of HCD herb exacts or the pure compounds were reported to be through multiple cellular or molecular mechanisms, such as induction of cancer cell apoptosis, differentiation and cell cycle arrest, inhibition of cancer cell growth, invasion and metastasis, and inhibition of tumor angiogenesis. In this review, we provide comprehensive analysis and summary of research progress and future prospects in this field to facilitate the further study and application of HCD herbs.

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is more than merely a respiratory disease, as it also presents with various neurological symptoms. SARS‐CoV‐2 may infect the central nervous system (CNS) and thus is neurotropic. However, the pathophysiological mechanism of coronavirus disease 2019 (COVID‐19)‐associated neuropathy remains unclear. Many studies have reported that SARS‐CoV‐2 enters the CNS through the hematogenous and neuronal routes, as well as through the main host neurological immune responses and cells involved in these responses. The neurological immune responses to COVID‐19 and potential mechanisms of the extensive neuroinflammation induced by SARS‐CoV‐2 have been investigated. Although CNS infection with SARS‐CoV‐2 was shown to lead to neuronal impairment, certain aspects of this mechanism remain controversial and require further analysis. In this review, we discussed the pathway and mechanisms of SARS‐CoV‐2 invasion in the CNS, and associated clinical manifestations, such as anosmia, headache, and hyposmia. Moreover, the mechanism of neurological damage caused by SARS‐CoV‐2 may provide potential treatment methods for patients presenting with SARS‐CoV‐2‐associated neuropathy.

Although hepatitis E virus (HEV) infection is a zoonosis, there is, currently, no standardized assay for quantitatively measuring anti-HEV antibody levels in HEV animal reservoirs. In this study, anti-HEV antibody positive serum from a rabbit (RS26) was calibrated by dose-response parallel line assay using the World Health Organization (WHO) reference standard for anti-HEV antibodies. After evaluating the stability of the RS26 serum, a quantification assay of anti-HEV antibodies using RS26 as a standard was developed and evaluated for both reproducibility and suitability to field studies. The anti-HEV antibody level of RS26 was calculated to be 39.54 IU/ml. A series of standard working serum for anti-HEV antibodies consisted of five serum dilutions (3.950 IU/ml, 1.975 IU/ml, 0.986 IU/ml, 0.494 IU/ml, and 0.247 IU/ml). The quantitative assay using RS26 showed good range and reproducibility, effectively measuring the dynamics of anti-HEV antibody concentrations in pigs and rabbits. In conclusion, we have developed a a stable and reproducible serum standard for the quantitation of anti-HEV antibodies. J. Med. Virol. 89:497-501, 2017. © 2016 Wiley Periodicals, Inc.

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder. The disease lacks specific clinical and radiological manifestations, which may delay a definitive diagnosis. We report the case of a 39-year-old man with pulmonary LYG who presented to a hospital after experiencing three months of fever, weight loss, dry cough and exertional dyspnea. He was initially misdiagnosed with pneumonia, granulomatosis with polyangiitis and infectious mononucleosis due to the non-specific manifestations of the disease. We herein present the clinical and radiological characteristics of this case and discuss the procedure for pathological diagnosis, which will likely help clinicians in making a timely definitive diagnosis of this disease.